Latest Conference Articles

December 11th 2022, 12:24am

ASH Annual Meeting and Exposition

The non-covalent BTK inhibitor pirtobrutinib showed high levels of response in heavily pretreated patients with Waldenström macroglobulinemia, regardless of prior treatment with a covalent BTK inhibitor.

December 10th 2022, 11:55pm

ASH Annual Meeting and Exposition

The GPRC5D- and CD3-directed bispecific antibody forimtamig led to high response rates in patients with relapsed or refractory multiple myeloma regardless of subcutaneous or intravenous administration, according to updated findings from a phase 1 dose-escalation study.

December 10th 2022, 11:20pm

ASH Annual Meeting and Exposition

The combination of rituximab and lenalidomide maintained improved progression-free survival compared with rituximab alone in patients with relapsed/refractory indolent non-Hodgkin lymphoma, according to 5-year findings from the phase 3 AUGMENT trial.

December 10th 2022, 10:05pm

ASH Annual Meeting and Exposition

Administration of teclistamab in combination with daratumumab and lenalidomide demonstrated promising overall response rates and tolerability in patients with relapsed/refractory multiple myeloma who had prior lenalidomide exposure, according to initial data from the phase 1b MajesTEC-2 trial.

December 10th 2022, 9:36pm

ASH Annual Meeting and Exposition

Treatment with the CD3/BCMA bispecific antibody elranatamab elicited an objective response rate by blinded independent central review of 61.0% in patients with penta- or triple-class refractory multiple myeloma who had not received a prior BCMA-targeted therapy.

December 10th 2022, 9:11pm

ASH Annual Meeting and Exposition

Sequential administration of lintuzumab-Ac225 after salvage chemotherapy proved to be safe and feasible, and to result in high response and minimal residual disease negativity rates in high-risk patients with relapsed/refractory acute myeloid leukemia.

December 10th 2022, 9:05pm

ASH Annual Meeting and Exposition

Talquetamab elicited overall response rates of higher than 70% when administered in weekly or every-other-week schedules in heavily pretreated patients with relapsed or refractory multiple myeloma.

December 10th 2022, 8:55pm

ASH Annual Meeting and Exposition

Olverembatinib was found to uphold clinical benefit and continued to have an acceptable safety profile in patients with BCR-ABL1 T315I-mutant chronic myeloid leukemia -chronic phase or -acute phase that is resistant to TKIs.

December 10th 2022, 7:52pm

ASH Annual Meeting and Exposition

Watchful waiting followed by sequential conditioning prior to allogeneic hematopoietic cell transplantation provided similar overall survival and leukemia-free survival to that achieved with intensive remission induction chemotherapy comprised of high-dose cytarabine and mitoxantrone followed by allogeneic hematopoietic cell transplantation in patients with relapsed or refractory acute myeloid leukemia.

December 10th 2022, 7:02pm

ASH Annual Meeting and Exposition

Glofitamab administered as a fixed 12-cycle regimen 7 days after obinutuzumab pretreatment elicited high, early, and durable responses in patients with relapsed/refractory mantle cell lymphoma who had undergone prior BTK inhibitor therapy.

December 10th 2022, 12:20am

San Antonio Breast Cancer Symposium

The addition of carboplatin to taxane-anthracycline chemotherapy led to a significant improvement in event-free survival and overall survival as neoadjuvant therapy in patients with operable and locally advanced triple-negative breast cancer.

December 10th 2022, 12:15am

San Antonio Breast Cancer Symposium

Sacituzumab govitecan prolonged survival vs treatment of physician’s choice in pretreated patients with hormone receptor–positive, HER2-negative metastatic breast cancer regardless of Trop-2 expression, according to updated findings from the phase 3 TROPiCS-02 trial.

December 9th 2022, 11:44pm

San Antonio Breast Cancer Symposium

Long-term clinical data failed to show a benefit of neoadjuvant olaparib (Lynparza) plus paclitaxel vs carboplatin plus paclitaxel in patients with HER2-negative early breast cancer with homologous recombination deficiency.

December 9th 2022, 11:43pm

San Antonio Breast Cancer Symposium

The addition of cemiplimab and REGN3767 to paclitaxel improved pathologic complete response vs paclitaxel alone in patients with triple-negative and hormone receptor–positive, HER2-negative breast cancer, according to data from the phase 2 I-SPY2 trial.

December 9th 2022, 10:45pm

San Antonio Breast Cancer Symposium

Mafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.

December 9th 2022, 10:05pm

San Antonio Breast Cancer Symposium

Trastuzumab deruxtecan, both as monotherapy and in combination with pertuzumab, displayed encouraging efficacy with no new safety signals among patients with HER2-positive metastatic breast cancer, according to findings from the dose expansion part of the phase 1b/2 DESTINY-Breast07 trial.

December 9th 2022, 9:01pm

ESMO Immuno-Oncology Congress

John Moroney, MD, discusses the evaluation of COM701 plus BMS-986207 and nivolumab in platinum-resistant ovarian cancer.

December 9th 2022, 8:59pm

ESMO Immuno-Oncology Congress

Oladapo Yeku, MD, PhD, FACP, discusses the evaluation of COM701 with nivolumab in patients with platinum-resistant epithelial ovarian cancer.

December 9th 2022, 6:00pm

San Antonio Breast Cancer Symposium

William Jacot, MD, PhD, discusses updated efficacy and safety results from the phase 2 AMALEE trial.

December 9th 2022, 2:00pm

ESMO Immuno-Oncology Congress

Neoadjuvant treatment with nivolumab (Opdivo) plus platinum doublet chemotherapy showed superior major pathological response rates and pathological complete response rates compared with nivolumab monotherapy among patients with resectable non–small cell lung cancer even for patients with a PD-L1 expression of 50% or greater.